Susquehanna International Group LLP Acquires 87,544 Shares of Artivion, Inc. $AORT

Susquehanna International Group LLP increased its holdings in Artivion, Inc. (NYSE:AORT) by 584.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 102,531 shares of the company’s stock after buying an additional 87,544 shares during the quarter. Susquehanna International Group LLP’s holdings in Artivion were worth $2,304,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Artivion in the 2nd quarter valued at approximately $149,965,000. Conestoga Capital Advisors LLC bought a new position in Artivion during the 1st quarter valued at about $43,044,000. Summit Partners Public Asset Management LLC acquired a new position in Artivion in the fourth quarter valued at about $39,401,000. Invesco Ltd. grew its stake in Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after buying an additional 748,119 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Artivion during the second quarter worth approximately $11,717,000. Institutional investors own 86.37% of the company’s stock.

Insider Buying and Selling

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 114,978 shares of company stock valued at $2,965,155 over the last ninety days. Insiders own 6.30% of the company’s stock.

Artivion Stock Performance

AORT stock opened at $26.77 on Monday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a twelve month low of $19.16 and a twelve month high of $48.25. The company has a market cap of $1.31 billion, a P/E ratio of -382.37 and a beta of 1.24. The business has a fifty day moving average of $25.64 and a 200-day moving average of $29.60.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The firm had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. As a group, equities research analysts expect that Artivion, Inc. will post 0.45 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on AORT shares. Canaccord Genuity Group boosted their target price on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Citizens Jmp reduced their price objective on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Finally, Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.